Progenics Pharmaceuticals — Merger or Acquisition (May 2020)
29 slides from Progenics Pharmaceuticals's merger presentation, May 12, 2020
Slide 1: Filed by Lantheus Holdings, Inc. Pursuant to Rule 425
Filed by Lantheus Holdings, Inc. Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Progenics Pharmaceuticals, Inc. Commission File No.: 000 – 23143 The following is a slide deck relating to the proposed
Slide 2: Corporate Presentation May 2020
Corporate Presentation May 2020
Slide 3: Safe Harbor Statements: Important Information For Investors And Stockholders
Safe Harbor Statements Important Information For Investors And Stockholders This document does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval in any jurisdiction in which such offer, solicitation or sale would be unlawf
Slide 4: Safe Harbor Statements: Cautionary Statement Regarding Forward-Looking Statements
Safe Harbor Statements Cautionary Statement Regarding Forward-Looking Statements This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties and are made pursuant to the safe harbor provision
Slide 5: The Lantheus Story
The Lantheus Story 4 1 Market Leader Where We Are Today 4 Strong Capital Position To Fund Our Future 2 Targeting Growing Markets 3 Enhancing Growth from a Position of Strength
Slide 6: Lantheus Overview
Lantheus Overview #1 in Ultrasound Contrast Agents Dynamic Pipeline Operational Excellence Leader in Radio-pharmaceuticals Company Overview Global leader in the development, manufacture and commercialization of innovative medical diagnostics Our products help healthcare professionals identify diseas
Slide 7: Corporate Timeline
Corporate Timeline 1956 New England nuclear (NEN) founded 1981 1991 2001 2008 DUPONT purchases NEN DuPont forms venture with Merck called DuPont Merck DuPont buys Merck’s interest, becomes DuPont Pharmaceuticals Bristol Myers Squibb Co. purchases DuPont Pharmaceuticals BMS sells BMS Medical Imaging
Slide 8: Current Product Portfolio
Current Product Portfolio * Based on 2019 Worldwide Revenue ($ in millions) ** Source for DEFINITY market share: AMR Echocardiography Monthly Monitor, December 2019. Source for TechneLite market share: LMI internal estimates. *** 3-year CAGR (2016-2019) Revenue 2019* / % of Revenue Key Product / U.S
Slide 9: A Corporate Footprint Balanced By Unique Core Competencies
A Corporate Footprint Balanced By Unique Core Competencies * - We currently believe that, if approved by the FDA, the modified formulation could become commercially available in early 2021, although that timing cannot be assured. ** - Group Purchasing Organizations (GPOs) and Integrated Delivery Net
Slide 10: The Lantheus Story
The Lantheus Story 9 1 Market Leader Where We Are Today 4 Strong Capital Position To Fund Our Future 2 Targeting Growing Markets 3 Enhancing Growth from a Position of Strength
Slide 11: Large, Growing Global Markets
Large, Growing Global Markets * 5-year CAGR Source: GlobalData, Sept 2019 Source: MedRaysIntell, July 2019 Global Diagnostic Imaging Market ($B) Global Nuclear Medicine Market ($B) 12% CAGR 2019 – 2024* 14% CAGR 2019 – 2024*
Slide 12: Large Echocardiography Market Opportunity in the U.S. Alone
Large Echocardiography Market Opportunity — in the U.S. Alone ~2% Annual Growth Rate in Total Echocardiograms Source: AMR Echocardiography Monthly Monitor, December 2019 Note: Circles not drawn to scale Currently, Lantheus has ~80% market share of contrast imaging agent use. Current addressable mark
Slide 13: U.S. Tc-99m Market: ~$225 MM
U.S. Tc-99m Market: ~$225 MM Generator Market Driven Primarily by Cardiac Studies 12 MM = millions Source: AMR PADDS 2018 database, LMI internal market assessment * - LMI estimate for market share 2016 - 2019 Tc99m SPECT Annual Procedure Volume 9 – 10 million ~ ~ Annual Tc-99m SPECT Studies Other Tc
Slide 14: The Lantheus Story
The Lantheus Story 1 Market Leader Where We Are Today 4 Strong Capital Position To Fund Our Future 2 Targeting Growing Markets 3 Enhancing Growth from a Position of Strength
Slide 15: Lantheus 2.0 Areas of Strategic Focus
Lantheus 2.0 Areas of Strategic Focus* Note: Assumes closing of the merger with Progenics * - Neuroendocrine tumors Microbubbles Nuclear 2.0 Diagnostics Nuclear 2.0 Theranostics Pro Forma Product Portfolio Flurpiridaz F 18 Cardiac Multi-Therapeutic Applications NM-01 Immuno-Oncology LMI 1195 Neuroen
Slide 16: Progenics Acquisition - Executing a Compelling Strategic Opportunity
Progenics Acquisition - Executing a Compelling Strategic Opportunity Robust portfolio and pipeline of precision diagnostic and therapeutic products Proven leadership with strong commercial, operational and financial expertise; aligned with stockholder interests Sustainable and diversified revenue gr
Slide 17: Well-Balanced Portfolio of Marketed Assets: DEFINITY and Radiopharmaceuticals
DEFINITY Unparalleled market and brand position Dedicated salesforce drives advocacy and awareness Long-standing relationships with sonographers/echocardiologists Four Orange Book-listed patents in total Room temperature formulation has patent protection to 2035 Radiopharmaceuticals Wide range of di
Slide 18: AZEDRA and Portfolio of Key Products
AZEDRA First/only FDA-approved treatment for adults and pediatric patients 12 and older with iobenguane scan positive, unresectable, locally advanced or metastatic PPGL* who require systemic anticancer therapy Additionally a Portfolio of Key Products Addressing Unique Unmet Needs in Oncology RELISTO
Slide 19: Robust Combined Pipeline with Clear Value Drivers
Legend: DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 FILING DEFINITY Flurpiridaz F 18 LMI 1195 F 18 Cerevast Retinal Vein Occlusion Technology CarThera SonoCloud for Glioblastoma NM-01 99mTc PyL™ F 18 1095 I-131 1404 99mTc PSMA TTC Th 227 PSMA AI NCE/NBE Precision Diagnostic Robust Combined Pipelin
Slide 20: Proven Management Team With Deep Industry Expertise
Proven Management Team With Deep Industry Expertise Mary Anne Heino President and Chief Executive Officer Mike Duffy SVP — Law and Public Policy, General Counsel Robert Marshall Chief Financial Officer and Treasurer John Bolla Chief Operations Officer Etienne Montagut SVP — Corporate Development Car
Slide 21: The Lantheus Story
The Lantheus Story 1 Market Leader Where We Are Today 4 Strong Capital Position to Fund Our Future 2 Targeting Growth Markets 3 Enhancing Growth from a Position of Strength
Slide 22: Strong Balance Sheet and Financial Flexibility
Strong Balance Sheet and Financial Flexibility Strong Balance Sheet (Q1 2020)* Decline in Net Debt Resources (Q1 2020)* Generating $40-60M Free Cash Flow annually $365M $193M Net Leverage Cash on hand Available revolving credit $96M $200M 1.4x Figures as of Q1 2020. On April 1, 2020, the Company dre
Slide 23: Appendix
Appendix
Slide 24: Robust Combined Pipeline: Life Cycle Management
Robust Combined Pipeline with Clear Value Drivers Life Cycle Management DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 FILING DEFINITY Octafluoropropane - Room Temperature Formulation Development Partners Lantheus developing
Slide 25: Robust Combined Pipeline: Precision Diagnostic
Robust Combined Pipeline with Clear Value Drivers NCE: New Chemical Entity GE Healthcare is conducting the second phase 3 study. Ongoing Phase 1 clinical development conducted by NanoMab. NCE Precision Diagnostic DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 FILING Flurpiridaz F 18 PET Myocardial Pe
Slide 26: Robust Combined Pipeline: Therapeutics
Robust Combined Pipeline with Clear Value Drivers NCE: New Chemical Entity; NBE New Biologic Entity NCE/NBE Therapeutics DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 FILING Cerevast Retinal Vein Occlusion Technology Proprietary therapeutic ultrasound technology - Microbubble Franchise CarThera Sono
Slide 27: Robust Combined Pipeline: Digital Solution
Robust Combined Pipeline with Clear Value Drivers Digital Solution DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 FILING PSMA AI Automated reading of PSMA images using AI Development Partners Progenics developing
Slide 28: Radiopharmaceutical Business Model Defined by Unique Features
Radiopharmaceutical Business Model Defined by Unique Features Highly Complex – Supply Chain & Logistics Specialized - Product Development & Commercialization Capabilities in Nuclear Medicine Highly Regulated - >30 Local, State, Federal, & International Agencies Stakeholders - Strong Relationships wi
Slide 29: Corporate Presentation May 2020
Corporate Presentation May 2020
Progenics Pharmaceuticals — Merger or Acquisition (May 2020) on 6ix